The role of naturally activated nigella sativa (rabicabir)‎ in original Baraka capsules as an effective antiviral drug in hepatitis C virus and its complications

Abstract EN

Aim : The study is aiming to determine the efficacy and tolerance of the new invented naturally activated Nigella Sativa (Rabicabir) that exists in Original Baraka capsules as a basic antiviral treatment of hepatitis C virus and its complications. Patients and Methods : One hundred patients with chronic active hepatitis C virus confirmed Histopathologicaly and associated with high HCV-RNA PCR quantitatively were treated with the new invented drug extract (registered as an invented drug in Academy of scientific research and technology (patent office) of ministry of state for scientific research, Egypt under the name of Malak Liver (Rabicabir) capsules ; patent number 200605216 and developed in France through "Laboratoire d’Innovation in design and development drugs delivery devices " located in Clermont-ferrand.

Medical statistical analyses of random 100 patients of HCV were treated by the new invented drug in multi-hepatological centres all over Egypt in the period from January 2002 to October 2005. Results : Laboratory investigations found that; regarding liver function tests, Rabicabir capsules show normalized liver enzymes in all patients.

Regarding HCV-RNA PCR quantitative assessment, 70 % of Rabicabir treated patients had complete remission of HCV viraemia while 30 % of Rabicabir treated patients had partial remission with significant improvement of HCV viraemia level.

Radiological investigations found that; Ultrasonography abdomen examination for liver, Rabicabir capsules show significant improvement of liver condition, size and parenchymal affection in 67.5 % of patients.

For portal vein diameter, Rabicabir capsules show significant improvement and normalization of portal vein diameter and pressure in all patients.

For spleen examination, Rabicabir capsules show significant improvement of spleen condition, size and activity in 96 % of patients.

On the level of liver biopsy and histopathological examination, regarding HCV chronic hepatitis activity scoring, 69 % Rabicabir treated patients improved to mild HCV activity score while 1 % of Rabicabir treated patients showed complete assisted activity, yet 30 % showed less improvement.

On the level of general conditions of patients, 98% of patients had general condition improvement (improvement of effort, no fatigue, no exhaustion, no weakness, increase the appetite, weight regain, disappearance of nausea sensation, significant decrease of daily bleeding from nose, gum and mouth, significant elevation of Prothrombin secretion, disappearance of spasms sensation in the right hand side of the abdomen, disappearance of dark pigmentation on the face and legs, and gradual disappearance of pale yellow colour of eye and nails, indicating that liver starts to work again.

On the level of liver fibrosis(40- 45) grading system, 10 % of treated patients got significant improvement and had very minimal fibrosis, 65 % of treated patients improved and had mild liver fibrosis, while 25 % of treated patients showed minimal improvement of liver fibrosis.

The new invented drug is given to HCV patients with their approval consent in a dose of three grams per day after meals for a period ranged from 24-48 months according to HCV viraemia severity and liver condition. Conclusion : The new invented drug Rabicabir capsules is safe without any adverse reactions and has very good tolerability.